Page 1090 - Hematology_ Basic Principles and Practice ( PDFDrive )

969.e4 Part VII Hematologic Malignancies

141. Hyde RK, Liu PP: GATA2 mutations lead to MDS and AML. Nat 163. Christiansen DH, Andersen MK, Desta F, et al: Mutations of genes
Genet 43(10):926–927, 2011. in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction
142. Ostergaard P, Simpson MA, Connell FC, et al: Mutations in GATA2 pathway in therapy-related myelodysplasia and acute myeloid leukemia.
cause primary lymphedema associated with a predisposition to acute Leukemia 19(12):2232–2240, 2005.
myeloid leukemia (Emberger syndrome). Nat Genet 43(10):929–931, 164. Score J, Hidalgo-Curtis C, Jones AV, et al: Inactivation of poly-
2011. comb repressive complex 2 components in myeloproliferative and
143. Hsu AP, Sampaio EP, Khan J, et al: Mutations in GATA2 are associated myelodysplastic/myeloproliferative neoplasms. Blood 119(5):1208–
with the autosomal dominant and sporadic monocytopenia and myco- 1213, 2012.
bacterial infection (MonoMAC) syndrome. Blood 118(10):2653–2655, 165. Makishima H, Cazzolli H, Szpurka H, et al: Mutations of e3 ubiquitin
2011. ligase cbl family members constitute a novel common pathogenic lesion
144. Dickinson RE, Griffin H, Bigley V, et al: Exome sequencing identifies in myeloid malignancies. J Clin Oncol 27(36):6109–6116, 2009.
GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK 166. Di Giacomo D, Lema Fernandez AG, Pierini T, et al: The GNAS1 gene
lymphoid deficiency. Blood 118(10):2656–2658, 2011. in myelodysplastic syndromes (MDS). Leuk Res 38(7):804–807, 2014.
145. Dickinson RE, Milne P, Jardine L, et al: The evolution of cellular 167. Yoda A, Adelmant G, Tamburini J, et al: Mutations in G protein β
deficiency in GATA2 mutation. Blood 123(6):863–874, 2014. subunits promote transformation and kinase inhibitor resistance. Nat
146. Micol J-B, Abdel-Wahab O: Collaborating constitutive and somatic Med 21(1):71–75, 2014.
genetic events in myeloid malignancies: ASXL1 mutations in patients 168. Jankowska AM, Gondek LP, Szpurka H, et al: Base excision repair
with germline GATA2 mutations. Haematologica 99(2):201–203, 2014. dysfunction in a subgroup of patients with myelodysplastic syndrome.
147. Kaneko H, Misawa S, Horiike S, et al: TP53 mutations emerge at early Leukemia 22(3):551–558, 2008.
phase of myelodysplastic syndrome and are associated with complex 169. Kawankar N, Vundinti BR: Cytogenetic abnormalities in myelodysplas-
chromosomal abnormalities. Blood 85(8):2189–2193, 1995. tic syndrome: an overview. Hematology 16(3):131–138, 2011.
148. Lindsley RC, Mar BG, Mazzola E, et al: Acute myeloid leukemia ontog- 170. Swerdlow S, Campo E, Harris N, et al WHO Classification of Tumours
eny is defined by distinct somatic mutations. Blood 125:1367–1376, of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of
2015. Tumours). 4th ed. 2008.
149. Jadersten M, Saft L, Smith A: TP53 mutations in low-risk myelodys- 171. Ebert BL: Molecular dissection of the 5q deletion in myelodysplastic
plastic syndromes with del(5q) predict disease progression. J Clin Oncol syndrome. Semin Oncol 38(5):621–626, 2011.
29(15):1971–1979, 2011. 172. Pedersen B: Anatomy of the 5q- deletion: different sex ratios and
150. Wong TN, Ramsingh G, Young AL, et al: Role of TP53 mutations in deleted 5q bands in MDS and AML. Leukemia 10(12):1883–1890,
the origin and evolution of therapy-related acute myeloid leukaemia. 1996.
Nature 518:552–555, 2014. 173. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic
151. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 syndrome with chromosome 5q deletion. N Engl J Med 355(14):1456–
internal tandem duplication in patients with acute myeloid leukemia 1465, 2006.
(AML) adds important prognostic information to cytogenetic risk 174. Boultwood J, Pellagatti A, Wainscoat JS: Haploinsufficiency of
group and response to the first cycle of chemotherapy: analysis of 854 ribosomal proteins and p53 activation in anemia: Diamond-Blackfan
patients from the United Kingdom Medical Research Council AML 10 anemia and the 5q- syndrome. Adv Biol Regul 52(1):196–203, 2012.
and 12 trials. Blood 98(6):1752–1759, 2001. 175. Ebert BL, Pretz J, Bosco J, et al: Identification of RPS14 as a 5q- syn-
152. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation drome gene by RNA interference screen. Nature 451(7176):335–339,
of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779– 2008.
1790, 2005. 176. Kumar MS, Narla A, Nonami A, et al: Coordinate loss of a microRNA
153. Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myelo- and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
proliferative and other myeloid disorders: a study of 1182 patients. Blood 118(17):4666–4673, 2011.
Blood 108(10):3472–3476, 2006. 177. Schneider RK, Ademà V, Heckl D, et al: Role of casein kinase 1A1
154. Furitsu T, Tsujimura T, Tono T, et al: Identification of mutations in in the biology and targeted therapy of del(5q) MDS. Cancer Cell
the coding sequence of the proto-oncogene c-kit in a human mast 26(4):509–520, 2014.
cell leukemia cell line causing ligand-independent activation of c-kit 178. Stoddart A, Fernald AA, Wang J, et al: Haploinsufficiency of del(5q)
product. J Clin Invest 92(4):1736–1744, 1993. genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid
155. Bains A, Luthra R, Medeiros LJ, et al: FLT3 and NPM1 mutations leukemia in mice. Blood 123(7):1069–1078, 2014.
in myelodysplastic syndromes: Frequency and potential value for 179. Chen TH-P, Kambal A, Krysiak K, et al: Knockdown of Hspa9, a
predicting progression to acute myeloid leukemia. Am J Clin Pathol del(5q31.2) gene, results in a decrease in hematopoietic progenitors in
135(1):62–69, 2011. mice. Blood 117(5):1530–1539, 2011.
156. Gallagher A, Darley R, Padua RA: RAS and the myelodysplastic 180. Sportoletti P, Grisendi S, Majid SM, et al: Npm1 is a haploinsufficient
syndromes. Pathol Biol (Paris) 45(7):561–568, 1997. suppressor of myeloid and lymphoid malignancies in the mouse. Blood
157. Side LE, Curtiss NP, Teel K, et al: RAS, FLT3, and TP53 mutations 111(7):3859–3862, 2008.
in therapy-related myeloid malignancies with abnormalities of chromo- 181. Horrigan SK, Arbieva ZH, Xie HY, et al: Delineation of a minimal
somes 5 and 7. Genes Chromosomes Cancer 39(3):217–223, 2004. interval and identification of 9 candidates for a tumor suppressor gene
158. Steensma DP, Dewald GW, Lasho TL, et al: The JAK2 V617F activat- in malignant myeloid disorders on 5q31. Blood 95(7):2372–2377,
ing tyrosine kinase mutation is an infrequent event in both “atypical” 2000.
myeloproliferative disorders and myelodysplastic syndromes. Blood 182. Ebert BL: Genetic deletions in AML and MDS. Best Pract Res Clin
106(4):1207–1209, 2005. Haematol 23(4):457–461, 2010.
159. Hellstrom-Lindberg E, Cazzola M: The role of JAK2 mutations in 183. Kere J, Ruutu T, la Chapelle A: de. Monosomy 7 in granulocytes and
RARS and other MDS. Hematology Am Soc Hematol Educ Program monocytes in myelodysplastic syndrome. N Engl J Med 316(9):499–503,
52–59, 2008. 1987.
160. Kon A, Shih L-Y, Minamino M, et al: Recurrent mutations in multiple 184. Wong CC, Martincorena I, Rust AG, et al: Inactivating CUX1 muta-
components of the cohesin complex in myeloid neoplasms. Nat Genet tions promote tumorigenesis. Nat Genet 46(1):33–38, 2014.
45(10):1232–1237, 2013. 185. Le Beau M, Espinosa R, 3rd, Davis E, et al: Cytogenetic and molecular
161. Thota S, Viny A, Makishima H: Genetic alterations of the cohesin delineation of a region of chromosome 7 commonly deleted in malig-
complex genes in myeloid malignancies. Blood 8:2014–2024, 2014. nant myeloid diseases. Blood 88:1930–1935, 1996.
162. Tartaglia M, Niemeyer CM, Fragale A, et al: Somatic mutations in 186. Cordoba I, González-Porras JR, Nomdedeu B, et al: Better prognosis
PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syn- for patients with del(7q) than for patients with monosomy 7 in myelo-
dromes and acute myeloid leukemia. Nat Genet 34(2):148–150, 2003. dysplastic syndrome. Cancer 118(1):127–133, 2012.